



University
of Glasgow

Conrad, N., McInnes, I. B., McMurray, J. J.V. and Sattar, N. (2022) Patients with a range of rheumatic diseases are at increased risk of cardiovascular disorders towards a re-evaluation of the European League against Rheumatism (EULAR)'s recommendations for cardiovascular risk management? *Annals of the Rheumatic Diseases*, (doi: 10.1136/ard-2022-223315).

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

<https://eprints.gla.ac.uk/287635/>

Deposited on: 5 January 2023

Enlighten – Research publications by members of the University of Glasgow
<https://eprints.gla.ac.uk>

Patients with a range of rheumatic diseases are at increased risk of cardiovascular disorders towards a re-evaluation of the European League against Rheumatism (EULAR)'s recommendations for cardiovascular risk management?

Nathalie Conrad¹, Iain B McInnes², John J V McMurray³, Naveed Sattar³

1. Department of Public Health and Primary Care, KU Leuven, Leuven, Flanders, Belgium
2. College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK
3. School of Cardiovascular & Metabolic Health, University of Glasgow, Glasgow, UK

Correspondence to Professor Naveed Sattar, School of Cardiovascular & Metabolic Health, University of Glasgow, Glasgow G12 8TA, UK; Naveed.Sattar@glasgow.ac.uk; Dr Nathalie Conrad; nathalie.conrad@kuleuven.be

The notion that patients with rheumatic disorders are at increased risk of developing cardiovascular diseases has been ongoing for many years and has sparked much debate concerning whether and when to initiate cardiovascular prevention therapies. The initiation of preventive therapies, such as blood pressure lowering drugs or statins, is usually recommended in patients at high risk of developing adverse cardiovascular outcomes. Accurately assessing an individual's cardiovascular risk is hence important. Until now, the modest size and duration of follow-up of available cohorts have been a barrier to precise quantification of cardiovascular risk in specific rheumatic disorders.¹ In particular, there is a lack of robust evidence about the rates of cardiovascular morbidity and mortality among people with diseases such as vasculitis, systemic sclerosis, or Sjögren's syndrome, and emerging evidence for excess risk in patients with systemic lupus erythematosus has not been validated in external cohorts.² The best evidence is available for rheumatoid arthritis, which has been shown to increase cardiovascular risk by approximately 50% beyond that explained by established risk factors.³ As a result, the current cardiovascular disease prevention guidelines from the European Society of Cardiology (2021) recommend a lower threshold for the initiation of preventive therapies in adults with rheumatoid arthritis, by multiplying patients' calculated risk score by 1.5, but make no mention of risk multipliers for other rheumatic diseases.⁴ The recent update of the European Alliance of Associations for Rheumatology (EULAR)'s recommendations (2022) did not endorse the use of any specific cardiovascular risk assessment tool nor risk multipliers for conditions beyond rheumatoid arthritis—although a thorough assessment of cardiovascular risk is recommended.⁵

A recent large-scale epidemiological study brings new evidence to this important clinical challenge. Using electronic health record data from 22 million individuals in the UK,⁶ Conrad *et al* examined 19 autoimmune disorders, including seven rheumatic diseases—axial spondyloarthritis, polymyalgia rheumatica, rheumatoid arthritis, Sjögren's syndrome, systemic lupus erythematosus, systemic sclerosis and vasculitis—and described their association with a broad range of cardiovascular

outcomes.⁶ This study showed that patients with rheumatic (or ‘connective tissue’) diseases, collectively, had an average 68% higher risk of cardiovascular disease over the period studied. Greater magnitudes of cardiovascular risk were observed for individuals with lupus and systemic sclerosis, for whom HRs were two to four times higher than in the general population. The study also demonstrated a ‘dose-related’ increase in cardiovascular risk with the number of autoimmune disorders present. Two findings were particularly striking. First, the earlier age of onset of cardiovascular disease in individuals with rheumatic and musculoskeletal diseases (RMD)—about 3 years earlier than controls. Second, the association between RMD and the full spectrum of cardiovascular diseases that emerged extended beyond atherosclerosis. The risk of thromboembolic disorders and degenerative heart disease, such as heart failure or non-rheumatic valve disorders, was substantially elevated, as were infectious and inflammatory cardiac diseases, including endocarditis, pericarditis and myocarditis. Importantly, the higher incidence of cardiovascular events in patients with rheumatic diseases was not sufficiently explained by differences in the prevalence of traditional atherosclerotic risk factors (which included elevated systolic and diastolic blood pressure, body mass index, smoking status, cholesterol, and type 2 diabetes) (table 1), although it must be noted that these variables were missing for a significant proportion of patients. In view of the similarity of trends in cardiovascular disease aetiology and population structure between the UK and other European countries, North America and Australasia,^{7 8} these findings are likely to be broadly applicable to many high income countries.

Table 1 Proposed multiplication factors for baseline cardiovascular risk score in individuals with rheumatic disorders

Rheumatic disease	HR 95% CI*	Adjusted HR 95% CI†	Proposed risk multiplier
Axial spondyloarthritis	1.97 (1.65 to 2.35)	1.91 (1.60 to 2.28)	1.5
Polymyalgia rheumatica	1.47 (1.40 to 1.54)	1.42 (1.36 to 1.49)	1.5
Rheumatoid arthritis	1.83 (1.74 to 1.92)	1.76 (1.67 to 1.85)	1.5
Sjögren's syndrome	2.08 (1.81 to 2.39)	2.15 (1.87 to 2.46)	1.5
Systemic lupus erythematosus	2.82 (2.38 to 3.33)	2.79 (2.37 to 3.29)	2
Systemic sclerosis	3.59 (2.81 to 4.59)	3.60 (2.81 to 4.62)	2.5
Vasculitis	1.87 (1.73 to 2.01)	1.78 (1.66 to 1.91)	1.5

HR and 95% CI for incident cardiovascular disease among patients with rheumatic disorders compared with matched controls, as reported by Conrad et al, ⁶ and proposed multiplication factors for cardiovascular risk scores informing the initiation of preventive therapies.

*Matched on age, sex, socioeconomic status, and region.

†Further adjusted for systolic and diastolic blood pressure, BMI, smoking, cholesterol and type 2 diabetes (sensitivity analysis).

BMI, body mass index.

Chronic inflammation is proposed as a major driver of cardiovascular disease pathogenesis and is a common denominator across many RMDs.⁹ Associations between inflammatory markers and cardiovascular disease observed in the general population^{10 11} and the efficacy of anti-inflammatory therapy in reducing cardiovascular disease¹²⁻¹⁴ further support this hypothesis. Several effector pathways likely play a role, including endothelial damage and impaired repair, altered stromal components of vascular tissues, cytokine, chemokine, immune complex and myeloid cell driven local inflammation, thrombocytopenia, thrombosis and interference with lipid profiles, in particular concerning their proinflammatory functional capacity. This plethora of potential mechanisms belies specific pathway understanding that can explain the observed epidemiology. Moreover, specific RMDs may accelerate cardiovascular risk by distinctive mechanisms.

These complex pathophysiological mechanisms in RMDs suggest that specific cardiovascular prevention measures might be needed for this patient population but also that due consideration across discrete conditions may be essential. Clinical trials are needed to test the effectiveness of existing and new cardiovascular prevention therapies specifically in patients with RMDs, and potential cardiovascular side effect of commonly prescribed antirheumatic drugs, non-steroidal anti-inflammatory drugs, biologics and corticosteroids must also be elucidated fully. While more cardiovascular outcome trials would also be useful in patients with RMD testing differing anti-inflammatory agents, placebo-controlled trials are near impossible given the need treat the systemic inflammation in patients with active disease. This means drug comparator trials are the best options, but these have generally been underpowered, and robust inferences become difficult.^{15 16}

Nevertheless, evidence from previous trials justifies using existing cardiovascular disease prevention measures. The JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial has shown that statin therapy improves cardiovascular outcomes among individuals with elevated inflammatory markers, even in subgroups with no other risk factors.¹⁷ The CANTOS (Cana kinumab Antiinflammatory Thrombosis Outcome Study), COLCOT (Colchicine Cardiovascular Outcomes Trial) and LoDoCo2 (Low-Dose Colchicine 2) trials have shown that inhibiting chronic inflammation, even without altering lipids or other risk factors, lowers rates of cardiovascular events.¹²⁻¹⁴ Finally, the TRACE-RA (Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients with Rheumatoid Arthritis) trial has shown that statins are safe in patients with rheumatoid arthritis, although caution is needed for women of childbearing age, and the same is likely to be true in other rheumatic conditions.¹⁸ Although TRACE-RA was underpowered, the point estimate provides preliminary evidence that statins are likely to be as effective in reducing cardiovascular risk in patients with rheumatoid arthritis as they are in other populations.¹⁸ Classical cardiovascular risk factors, such as blood pressure, obesity or smoking, are likely to interfere with disease-specific ones in patients with rheumatic disease and deserve to be managed carefully.

In light of these newly available large-scale epidemiological data and strong evidence of excess cardiovascular risk in several rheumatic conditions, we suggest a re-evaluation of EULAR's recommendations for cardiovascular risk management in patients with RMDs. We argue that recommendations should consider this new evidence of poorer cardiovascular health in numerous RMDs that should prompt cardiovascular screening and consequent prevention measures. The risk threshold for initiation of cardiovascular preventative drug therapies could be lowered for patients

with RMDs, a step already taken by the European Society of Cardiology for rheumatoid arthritis by introducing a risk multiplier.⁴ While risk multipliers may not fully take account of interactions with other risk factors, particularly age, could lead to imperfect model adjustment and, therefore, might provide imprecise individualised risk assessment, they are the best available option until personalised risk prediction tools are developed specifically for patients with RMD. To reflect the different orders of magnitude in cardiovascular risk between RMDs, we advocate a tailored approach, with different risk multipliers considered for each disease (table 1). The proposed risk multipliers were chosen to reflect the precise HRs for cardiovascular risk from the Conrad analysis and were calculated using the lower end of the adjusted HRs' 95% CI, rounded down to the next half integer. This conservative approach in part reflects potential overestimation of HRs from missing risk factors in adjustment and a possible declining trend in excess cardiovascular risk over time with better control of inflammation in many RMDs with disease-modifying biologics over this period, perhaps coupled to lower use of corticosteroids in many patients. One exception was made for polymyalgia rheumatica, for which we propose a risk multiplier of 1.5 despite a slightly lower HR, a decision which was taken to simplify use in routine clinical practice.

We did not have sufficient data to provide a risk assessment related to two other common inflammatory RMDs (gout and psoriatic arthritis) and further studies are needed to fill this gap.

Finally, although individually considered as rare disorders, collectively these conditions likely result in a high cardiovascular burden.⁶ In post hoc analyses performed for the present editorial, we calculated the collective prevalence of seven RMDs (axial spondyloarthritis, polymyalgia rheumatica, rheumatoid arthritis, Sjögren's syndrome, systemic lupus erythematosus, systemic sclerosis and vasculitis) in the UK in 2018, and found it to be 2.6% (3.2% in women, 1.9% in men).⁶ This means that there are about a third as many people living with RMDs as there are of type 2 diabetes, which currently affects 6.28% of the worldwide population,¹⁹ and further supports the strong public health imperative to protect these patients from cardiovascular disease.

Ethics statements

Patient consent for publication

Not applicable.

Ethics approval

Not applicable.

Acknowledgments

The authors thank Liz Coyle, University of Glasgow, for her assistance in the preparation of this article.

References

- 1 Peters MJL, Nurmohamed MT. Cardiovascular risk management in rheumatoid arthritis: are we still waiting for the first step? *Arthritis Res Ther* 2013;15:111.
- 2 Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. *BMJ* 2017;357:j2099.
- 3 Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. *Ann Rheum Dis* 2017;76:17–28.
- 4 Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J* 2021;42:3227–337.
- 5 Drosos GC, Vedder D, Houben E, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. *Ann Rheum Dis* 2022;81:768–79.
- 6 Conrad N, Verbeke G, Molenberghs G, et al. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. *Lancet* 2022;400:733–43.
- 7 United Nations,, Department of Economic and Social Affairs,, Population Division. World population ageing 2015 (ST/ESA/SER.A/390), 2015. Available: https://www.un.org/en/development/desa/population/publications/pdf/ageing/WPA2015_Report.pdf [Accessed 16 Nov 2022].
- 8 Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative metaanalysis of 102 prospective studies. *Lancet* 2010;375:2215–22.
- 9 Manzi S, Wasko MC. Inflammation-Mediated rheumatic diseases and atherosclerosis. *Ann Rheum Dis* 2000;59:321–5.
- 10 Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, et al. CReactive protein, fibrinogen, and cardiovascular disease prediction. *N Engl J Med* 2012;367:1310–20.
- 11 Ridker PM. High-Sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. *Am Heart J* 2004;148:S19–26.
- 12 Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N Engl J Med* 2017;377:1119–31.
- 13 Tardif J-C, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. *N Engl J Med* 2019;381:2497–505.
- 14 Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. *N Engl J Med* 2020;383:1838–47.
- 15 Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. *N Engl J Med* 2022;386:316–26.
- 16 Giles JT, Sattar N, Gabriel S, et al. Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. *Arthritis Rheumatol* 2020;72:31–40.
- 17 Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med* 2008;359:2195–207.

18 Kitas GD, Nightingale P, Armitage J, et al. A multicenter, randomized, placebocontrolled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis. *Arthritis Rheumatol* 2019;71:1437–49.

19 Khan MAB, Hashim MJ, King JK, et al. Epidemiology of Type 2 diabetes - Global burden of disease and forecasted trends. *J Epidemiol Glob Health* 2020;10:107–11.